Hyperlactatemia is associated with increased risks of long-term mortality and major adverse cardiovascular events in sepsis survivors

Serum lactate is a potentially valuable biomarker for risk assessment for patients with sepsis, as hyperlactatemia is associated with elevated short-term mortality risks. However, the associations between hyperlactatemia and long-term clinical outcomes in sepsis survivors remain unknown. The objecti...

Full description

Saved in:
Bibliographic Details
Published inInfectious diseases (London, England) Vol. 55; no. 8; pp. 576 - 584
Main Authors Ou, Shu-Yu, Lee, Yi-Jung, Chou, Yu-Mei, Sun, Gwo-Ching, Chia, Yuan-Yi
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 03.08.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Serum lactate is a potentially valuable biomarker for risk assessment for patients with sepsis, as hyperlactatemia is associated with elevated short-term mortality risks. However, the associations between hyperlactatemia and long-term clinical outcomes in sepsis survivors remain unknown. The objective of this study was to investigate whether hyperlactatemia at the time of hospitalisation for sepsis was associated with worse long-term clinical outcomes in sepsis survivors. In total, of 4983 sepsis survivors aged ≥ 20 years were enrolled in this study between January 1, 2012, and December 31, 2018. They were divided into low (≤18 mg/dL; n = 2698) and high (>18 mg/dL; n = 2285) lactate groups. The high lactate group was then matched 1:1 by propensity-score method to the low lactate group. The outcomes of interest were all-cause mortality, major adverse cardiac events (MACEs), ischaemic stroke, myocardial infarction, hospitalisation for heart failure, and end-stage renal disease. After propensity score matching, the high lactate group had greater risks of all-cause mortality (hazard ratio [HR] 1.54, 95% confidence interval [CI] 1.41-1.67), MACEs (HR 1.53, 95% CI 1.29-1.81), ischaemic stroke (HR 1.47, 95% CI 1.19-1.81), myocardial infarction (HR 1.52, 95% CI 1.17-1.99), and end-stage renal disease (HR 1.42, 95% CI 1.16-1.72). Subgroup analyses stratified by baseline renal function revealed almost similarity across groups. We found that hyperlactatemia is associated with long-term risks of mortality and MACEs in sepsis survivors. Physicians may consider more aggressive and prompter management of sepsis in patients who present with hyperlactatemia to improve long-term prognoses.
AbstractList Serum lactate is a potentially valuable biomarker for risk assessment for patients with sepsis, as hyperlactatemia is associated with elevated short-term mortality risks. However, the associations between hyperlactatemia and long-term clinical outcomes in sepsis survivors remain unknown. The objective of this study was to investigate whether hyperlactatemia at the time of hospitalisation for sepsis was associated with worse long-term clinical outcomes in sepsis survivors. In total, of 4983 sepsis survivors aged ≥ 20 years were enrolled in this study between January 1, 2012, and December 31, 2018. They were divided into low (≤18 mg/dL; n = 2698) and high (>18 mg/dL; n = 2285) lactate groups. The high lactate group was then matched 1:1 by propensity-score method to the low lactate group. The outcomes of interest were all-cause mortality, major adverse cardiac events (MACEs), ischaemic stroke, myocardial infarction, hospitalisation for heart failure, and end-stage renal disease. After propensity score matching, the high lactate group had greater risks of all-cause mortality (hazard ratio [HR] 1.54, 95% confidence interval [CI] 1.41-1.67), MACEs (HR 1.53, 95% CI 1.29-1.81), ischaemic stroke (HR 1.47, 95% CI 1.19-1.81), myocardial infarction (HR 1.52, 95% CI 1.17-1.99), and end-stage renal disease (HR 1.42, 95% CI 1.16-1.72). Subgroup analyses stratified by baseline renal function revealed almost similarity across groups. We found that hyperlactatemia is associated with long-term risks of mortality and MACEs in sepsis survivors. Physicians may consider more aggressive and prompter management of sepsis in patients who present with hyperlactatemia to improve long-term prognoses.
Serum lactate is a potentially valuable biomarker for risk assessment for patients with sepsis, as hyperlactatemia is associated with elevated short-term mortality risks. However, the associations between hyperlactatemia and long-term clinical outcomes in sepsis survivors remain unknown. The objective of this study was to investigate whether hyperlactatemia at the time of hospitalisation for sepsis was associated with worse long-term clinical outcomes in sepsis survivors. In total, of 4983 sepsis survivors aged ≥ 20 years were enrolled in this study between January 1, 2012, and December 31, 2018. They were divided into low (≤18 mg/dL;  = 2698) and high (>18 mg/dL;  = 2285) lactate groups. The high lactate group was then matched 1:1 by propensity-score method to the low lactate group. The outcomes of interest were all-cause mortality, major adverse cardiac events (MACEs), ischaemic stroke, myocardial infarction, hospitalisation for heart failure, and end-stage renal disease. After propensity score matching, the high lactate group had greater risks of all-cause mortality (hazard ratio [HR] 1.54, 95% confidence interval [CI] 1.41-1.67), MACEs (HR 1.53, 95% CI 1.29-1.81), ischaemic stroke (HR 1.47, 95% CI 1.19-1.81), myocardial infarction (HR 1.52, 95% CI 1.17-1.99), and end-stage renal disease (HR 1.42, 95% CI 1.16-1.72). Subgroup analyses stratified by baseline renal function revealed almost similarity across groups. We found that hyperlactatemia is associated with long-term risks of mortality and MACEs in sepsis survivors. Physicians may consider more aggressive and prompter management of sepsis in patients who present with hyperlactatemia to improve long-term prognoses.
INTRODUCTIONSerum lactate is a potentially valuable biomarker for risk assessment for patients with sepsis, as hyperlactatemia is associated with elevated short-term mortality risks. However, the associations between hyperlactatemia and long-term clinical outcomes in sepsis survivors remain unknown. The objective of this study was to investigate whether hyperlactatemia at the time of hospitalisation for sepsis was associated with worse long-term clinical outcomes in sepsis survivors. METHODSIn total, of 4983 sepsis survivors aged ≥ 20 years were enrolled in this study between January 1, 2012, and December 31, 2018. They were divided into low (≤18 mg/dL; n = 2698) and high (>18 mg/dL; n = 2285) lactate groups. The high lactate group was then matched 1:1 by propensity-score method to the low lactate group. The outcomes of interest were all-cause mortality, major adverse cardiac events (MACEs), ischaemic stroke, myocardial infarction, hospitalisation for heart failure, and end-stage renal disease. RESULTSAfter propensity score matching, the high lactate group had greater risks of all-cause mortality (hazard ratio [HR] 1.54, 95% confidence interval [CI] 1.41-1.67), MACEs (HR 1.53, 95% CI 1.29-1.81), ischaemic stroke (HR 1.47, 95% CI 1.19-1.81), myocardial infarction (HR 1.52, 95% CI 1.17-1.99), and end-stage renal disease (HR 1.42, 95% CI 1.16-1.72). Subgroup analyses stratified by baseline renal function revealed almost similarity across groups. CONCLUSIONWe found that hyperlactatemia is associated with long-term risks of mortality and MACEs in sepsis survivors. Physicians may consider more aggressive and prompter management of sepsis in patients who present with hyperlactatemia to improve long-term prognoses.
Author Chou, Yu-Mei
Chia, Yuan-Yi
Ou, Shu-Yu
Sun, Gwo-Ching
Lee, Yi-Jung
Author_xml – sequence: 1
  givenname: Shu-Yu
  surname: Ou
  fullname: Ou, Shu-Yu
  organization: Department of Anesthesiology, Kaohsiung Veterans General Hospital
– sequence: 2
  givenname: Yi-Jung
  surname: Lee
  fullname: Lee, Yi-Jung
  organization: School of Medicine, National Yang Ming Chiao Tung University
– sequence: 3
  givenname: Yu-Mei
  surname: Chou
  fullname: Chou, Yu-Mei
  organization: Department of Anesthesiology, Kaohsiung Veterans General Hospital
– sequence: 4
  givenname: Gwo-Ching
  surname: Sun
  fullname: Sun, Gwo-Ching
  organization: Institute of Clinical Medicine, National Cheng Kung University
– sequence: 5
  givenname: Yuan-Yi
  surname: Chia
  fullname: Chia, Yuan-Yi
  organization: School of Nursing, Fooyin University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37334716$$D View this record in MEDLINE/PubMed
BookMark eNp9UU1v1DAQtVARLUt_AshHLln8kdjJDVQVilSJC5ytWccBlyReZpxU-wP433i12x45zYfevKc37zW7mNMcGHsrxVaKVnxQ2ta10s1WCaW3SimtrH7Bro77qla1vnjudXPJrokehBBSd52S8hW71Fbr2kpzxf7eHfYBR_AZcpgi8EgciJKPZe75Y8y_eJw9BqAyYqTfxNPAxzT_rHLAiU8JM4wxHzjMPZ_gISGHfg1IgXvAPqYVyC8jIA9rmDMVOk5hT0WIFlzjmpDesJcDjBSuz3XDfny-_X5zV91_-_L15tN95bWsczV0BhpVTDRSGym01DsIrfGtbSwMINpiy4pGiALrhekaO0Bodr2RNkBnBr1h70-8e0x_lkDZTZF8GEeYQ1rIqVZZY7QpzBvWnKAeExGGwe0xToAHJ4U7huCeQnDHENw5hHL37iyx7KbQP189vbwAPp4AcR4STvCYcOxdhsOYcECYfSSn_6_xD1Tfmeg
Cites_doi 10.5935/0103-507X.20130047
10.1016/j.resuscitation.2011.06.015
10.1053/j.ajkd.2010.02.344
10.1056/NEJMra1208623
10.1097/01.ccm.0000132904.35713.a7
10.1186/s13054-015-1014-6
10.1378/chest.11-0352
10.3389/fnut.2021.783164
10.1001/jamapediatrics.2016.3681
10.1164/rccm.201510-2023OC
10.1097/CCM.0000000000000742
10.1097/SHK.0000000000000772
10.1186/s13054-018-2186-7
10.1186/1757-7241-19-74
10.1001/jama.2016.0287
10.1016/j.annemergmed.2004.12.006
10.1007/s40121-023-00765-6
10.1177/1178633719862776
10.1007/s00134-007-0563-9
10.1001/jama.2012.3954
10.3389/fmed.2022.809292
10.1038/s41598-021-99581-6
10.1186/s13613-021-00893-7
10.1186/s13613-021-00937-y
10.1186/2110-5820-3-6
10.1186/s13054-014-0503-3
10.5935/0103-507X.20170021
10.1186/s13054-016-1403-5
10.4143/crt.2018.360
10.1186/s13049-017-0415-8
10.4103/0970-9185.81819
10.1161/JAHA.122.028882
10.1053/j.ajkd.2012.06.016
10.3947/ic.2017.49.1.10
ContentType Journal Article
Copyright 2023 Society for Scandinavian Journal of Infectious Diseases 2023
Copyright_xml – notice: 2023 Society for Scandinavian Journal of Infectious Diseases 2023
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1080/23744235.2023.2223273
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2374-4243
EndPage 584
ExternalDocumentID 10_1080_23744235_2023_2223273
37334716
2223273
Genre Research Articles
Journal Article
GroupedDBID 00X
03L
0BK
0R~
53G
AAJNR
AALUX
AAMIU
AAPUL
AAQRR
ABBKH
ABDBF
ABEIZ
ABLJU
ABLKL
ABUPF
ACENM
ACFUF
ACGFS
ACLSK
ADCVX
ADFCX
ADRBQ
AECIN
AENEX
AEOZL
AEYQI
AFWLO
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AKBVH
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AMDAE
BABNJ
BLEHA
BOHLJ
CCCUG
DKSSO
EAP
EBS
EHN
EMB
ESX
IPNFZ
J.N
KRBQP
KSSTO
KWAYT
KYCEM
LJTGL
M4Z
O9-
RIG
RNANH
RVRKI
TFDNU
TFL
TFW
UEQFS
V1S
4.4
ABJNI
ABLIJ
ABXYU
ACIEZ
ALYBC
CGR
CUY
CVF
EAS
EBC
EBD
ECM
EIF
EJD
EMK
EMOBN
ENC
ENX
EPL
EPT
H13
NPM
NUSFT
Q~Q
SV3
TBQAZ
TDBHL
TERGH
TUROJ
TUS
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c314t-f96a52992513610313bae86c8757afa08733705006a5d06957fae5bd617ea96f3
ISSN 2374-4235
IngestDate Sat Aug 17 02:17:37 EDT 2024
Fri Aug 23 00:51:51 EDT 2024
Wed Oct 16 00:38:37 EDT 2024
Tue Jun 27 20:21:10 EDT 2023
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords major adverse cardiac events
mortality
End-stage renal disease
hyperlactatemia
sepsis survivor
sepsis
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c314t-f96a52992513610313bae86c8757afa08733705006a5d06957fae5bd617ea96f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 37334716
PQID 2827663631
PQPubID 23479
PageCount 9
ParticipantIDs crossref_primary_10_1080_23744235_2023_2223273
pubmed_primary_37334716
proquest_miscellaneous_2827663631
informaworld_taylorfrancis_310_1080_23744235_2023_2223273
PublicationCentury 2000
PublicationDate 2023-08-03
PublicationDateYYYYMMDD 2023-08-03
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-08-03
  day: 03
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Infectious diseases (London, England)
PublicationTitleAlternate Infect Dis (Lond)
PublicationYear 2023
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References CIT0030
CIT0010
CIT0032
CIT0031
CIT0012
CIT0034
CIT0011
CIT0033
CIT0014
CIT0013
CIT0016
CIT0015
CIT0018
CIT0017
CIT0019
CIT0021
CIT0020
CIT0001
CIT0023
CIT0022
CIT0003
CIT0025
CIT0002
CIT0024
CIT0005
CIT0027
CIT0004
CIT0026
CIT0007
CIT0029
CIT0006
CIT0028
CIT0009
CIT0008
References_xml – ident: CIT0016
  doi: 10.5935/0103-507X.20130047
– ident: CIT0015
  doi: 10.1016/j.resuscitation.2011.06.015
– ident: CIT0028
  doi: 10.1053/j.ajkd.2010.02.344
– ident: CIT0001
  doi: 10.1056/NEJMra1208623
– ident: CIT0009
  doi: 10.1097/01.ccm.0000132904.35713.a7
– ident: CIT0034
  doi: 10.1186/s13054-015-1014-6
– ident: CIT0004
  doi: 10.1378/chest.11-0352
– ident: CIT0010
  doi: 10.3389/fnut.2021.783164
– ident: CIT0019
  doi: 10.1001/jamapediatrics.2016.3681
– ident: CIT0030
  doi: 10.1164/rccm.201510-2023OC
– ident: CIT0007
  doi: 10.1097/CCM.0000000000000742
– ident: CIT0025
  doi: 10.1097/SHK.0000000000000772
– ident: CIT0003
  doi: 10.1186/s13054-018-2186-7
– ident: CIT0012
  doi: 10.1186/1757-7241-19-74
– ident: CIT0024
  doi: 10.1001/jama.2016.0287
– ident: CIT0018
  doi: 10.1016/j.annemergmed.2004.12.006
– ident: CIT0022
  doi: 10.1007/s40121-023-00765-6
– ident: CIT0029
  doi: 10.1177/1178633719862776
– ident: CIT0017
  doi: 10.1007/s00134-007-0563-9
– ident: CIT0026
  doi: 10.1001/jama.2012.3954
– ident: CIT0023
  doi: 10.3389/fmed.2022.809292
– ident: CIT0005
  doi: 10.1038/s41598-021-99581-6
– ident: CIT0008
  doi: 10.1186/s13613-021-00893-7
– ident: CIT0032
  doi: 10.1186/s13613-021-00937-y
– ident: CIT0014
  doi: 10.1186/2110-5820-3-6
– ident: CIT0006
  doi: 10.1186/s13054-014-0503-3
– ident: CIT0020
  doi: 10.5935/0103-507X.20170021
– ident: CIT0021
  doi: 10.1186/s13054-016-1403-5
– ident: CIT0002
  doi: 10.4143/crt.2018.360
– ident: CIT0013
  doi: 10.1186/s13049-017-0415-8
– ident: CIT0033
  doi: 10.4103/0970-9185.81819
– ident: CIT0031
  doi: 10.1161/JAHA.122.028882
– ident: CIT0027
  doi: 10.1053/j.ajkd.2012.06.016
– ident: CIT0011
  doi: 10.3947/ic.2017.49.1.10
SSID ssj0001399211
Score 2.4112797
Snippet Serum lactate is a potentially valuable biomarker for risk assessment for patients with sepsis, as hyperlactatemia is associated with elevated short-term...
INTRODUCTIONSerum lactate is a potentially valuable biomarker for risk assessment for patients with sepsis, as hyperlactatemia is associated with elevated...
SourceID proquest
crossref
pubmed
informaworld
SourceType Aggregation Database
Index Database
Publisher
StartPage 576
SubjectTerms Brain Ischemia - complications
End-stage renal disease
Humans
hyperlactatemia
Hyperlactatemia - complications
Hyperlactatemia - epidemiology
Ischemic Stroke - complications
Kidney Failure, Chronic - complications
Lactic Acid
major adverse cardiac events
mortality
Myocardial Infarction - complications
sepsis
Sepsis - complications
Sepsis - epidemiology
sepsis survivor
Stroke - complications
Survivors
Title Hyperlactatemia is associated with increased risks of long-term mortality and major adverse cardiovascular events in sepsis survivors
URI https://www.tandfonline.com/doi/abs/10.1080/23744235.2023.2223273
https://www.ncbi.nlm.nih.gov/pubmed/37334716
https://search.proquest.com/docview/2827663631
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLZKJyFeEPeNm4zEG3LJ4jiJHzdgVJPGUyetT5GT2qPTmkxLAxLv_Cj-HefYTpp2RdxeosppbTfny_Fn-_M5hLyGQZnnM5EwYA8Fi4oiZjJVmkkT5XImDRcJHk4--RSPT6PjM3E2GPzoqZaaZT4qvm09V_IvVoUysCuekv0Ly3aVQgF8BvvCFSwM1z-y8RgmkdeXqkDCuJgrTE6u_ONuVeXzEmlhrZ2I3Oo2LqvynKFHfrOw3Bt5OC6fL9QFKioxQzNq2NeFqjbQk9XO1voKg5jUDTiZL5XfDLpoBfFO2tXU7c5PvTVnSH91t7ELsJ8bNm021EHTOTtu_MhqFQiV_e60YSd6vtrNshV__FoxzAV-3l_GCLkV0fEOeJMbGUVWjjDkScSA9rndb90vcyGeWk_uAv56xKY9tyySuDfCC5eU7sbg4dSWWDM2NsJejpA-hS7ZykZcbn_nFtkJEynEkOwcHL4_PFot8GHIX5v_uet_e4IsDd5ubWWNG61Fzv31_MfyoMk9ctdPYOiBQ-N9MtDlA3L7xEs0HpLvG6Ck85quQEkRlLQDJbWgpJWhHShpB0oKQKEWlNSDkq6DkjpQQnXUgZJ2oHxETo8-TN6Nmc_1wQq-Hy2ZkbESQI2AbvMYU4_wXOk0LjDfgjIqSBPOk0DAGKHELIilSIzSIp8BAddKxoY_JsOyKvUuoYFKdKALnQeFiJI4yGUUaClmxhihYTqzR0btU86uXEiXbN9Hym3NkqFZMm-WPSL7tsiWFqvGwTTjv_ntq9ZwGThu3I1TpYbXMAvTMAG6H2OHnjiLdt3h8G-BNcZP_6PlZ-TO6j17TobL60a_AAK9zF96qP4E9JbDrQ
link.rule.ids 315,786,790,27955,27956
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hyperlactatemia+is+associated+with+increased+risks+of+long-term+mortality+and+major+adverse+cardiovascular+events+in+sepsis+survivors&rft.jtitle=Infectious+diseases+%28London%2C+England%29&rft.au=Ou%2C+Shu-Yu&rft.au=Lee%2C+Yi-Jung&rft.au=Chou%2C+Yu-Mei&rft.au=Sun%2C+Gwo-Ching&rft.date=2023-08-03&rft.pub=Taylor+%26+Francis&rft.issn=2374-4235&rft.eissn=2374-4243&rft.volume=55&rft.issue=8&rft.spage=576&rft.epage=584&rft_id=info:doi/10.1080%2F23744235.2023.2223273&rft.externalDocID=2223273
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2374-4235&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2374-4235&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2374-4235&client=summon